Authors

Latest:

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

George Sledge, Jr., MD

Latest:

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

George Somlo, MD

Latest:

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

George W. Sledge Jr, MD

Latest:

Looking for a Therapeutic Edge Among CDK Inhibitors

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

Georgia L. Wiesner, MD, MS

Latest:

Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Georgina Long, BSc, MBBS, FRACP, Melanoma Institute of Australia

Georgina Long, BSc, PhD, MBBS, FRACP

Latest:

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Georgina Long, MD, Melanoma Institute of Australia

Georgina Long, MD, PhD, Melanoma Institute of Australia at the University of Sydney

Georgina V. Long, BSc, PhD, MBBS

Latest:

Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.

Georgina V. Long, BSc, PhD, MBBS, FRACP

Latest:

Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Gerald J. Berry, MD, Stanford University

Gerald S. Falchook, MD

Latest:

Dr. Falchook on TRK Alterations in Lung Cancer

Gerald S. Falchook, MD, director, Drug Development, Sarah Cannon Research Institute, discusses TRK alterations in lung cancer.

Gerard E. Heath BS, Daniel A. Hamstra MD, Dean A. Shumway MD

Latest:

Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate Cancer

Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.

Gerold Meinhardt, MD

Latest:

Dr. Meinhardt on the Impact of the RESORCE Study in HCC

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Gerrit zur Hausen, MSc

Ghanshyam Yadav, MD

Latest:

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Ghassan Abou-Alfa, MD

Latest:

Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC

Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center

Ghassan K. Abou-Alfa, MD

Latest:

Safety Profiles of Available Therapies in Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.